BIOMAT Database Logo BIOMAT Database Logo

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. 2004

Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
Division of Structural Biology, The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.

We have used a structure-based approach to design a novel series of non-nucleoside inhibitors of HIV-1 RT (NNRTIs). Detailed analysis of a wide range of crystal structures of HIV-1 RT-NNRTI complexes together with data on drug resistance mutations has identified factors important for tight binding of inhibitors and resilience to mutations. Using this approach we have designed and synthesized a novel series of quinolone NNRTIs. Crystal structure analysis of four of these compounds in complexes with HIV-1 RT confirms the predicted binding modes. Members of this quinolone series retain high activity against the important resistance mutations in RT at Tyr181Cys and Leu100Ile.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015363 Quinolones A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID. Ketoquinoline,Ketoquinolines,Oxoquinoline,Oxoquinolines,Quinolinone,Quinolinones,Quinolone
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
[Mechanisms of HIV-1 drug resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors].
January 2011, Molekuliarnaia biologiia,
Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
[HIV resistance to non-nucleoside reverse transcriptase inhibitors].
August 2006, Virologie (Montrouge, France),
Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
December 2012, Journal of medicinal chemistry,
Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 2006, Bioorganic & medicinal chemistry letters,
Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
Nucleoside drug resistance in HIV-1 reverse transcriptase.
March 1995, Nature structural biology,
Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
August 2008, Journal of medicinal chemistry,
Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
September 2016, Journal of medicinal chemistry,
Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
Andrew L Hopkins, and Jingshan Ren, and John Milton, and Richard J Hazen, and Joseph H Chan, and David I Stuart, and David K Stammers
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.
December 2013, Future medicinal chemistry,
Copied contents to your clipboard!